Humuline Regular Patroon (Insulin Human (Rdna))

Humuline Regular Patroon is indicated for the management of blood glucose levels in patients with diabetes who require exogenous insulin.

• Type 1 diabetes mellitus when endogenous insulin production is insufficient.
• Type 2 diabetes mellitus requiring insulin supplementation to achieve glycemic targets.
• Situations of acute hyperglycemia where rapid insulin action is needed.
• Perioperative or hospital settings where tight glucose control is required.
• Gestational diabetes cases where oral agents are ineffective and insulin therapy is indicated.
• Adjunct therapy during steroid treatment that may raise blood glucose levels.

• Humuline Regular Patroon contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby reducing endogenous glucose production and contributing to lower plasma glucose concentrations.

Adverse reactions to Humuline Regular Patroon can vary in frequency and severity. The following lists reported events observed in clinical use.

Common

• Hypoglycemia (low blood glucose) – the most frequent reaction.
• Injection site reactions such as redness, swelling or itching.
• Lipodystrophy presenting as localized fat accumulation or loss.
• Weight gain associated with improved glycemic control.
• Nausea or abdominal discomfort occasionally reported after injection.
• Transient blurred vision during periods of rapid glucose change.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic anaphylactic reactions including rash, bronchospasm or angioedema.
• Edema or fluid retention causing peripheral swelling.
• Hypokalemia due to rapid intracellular shift of potassium.
• Insulin antibody formation that may alter drug efficacy.

When prescribing or using Humuline Regular Patroon, clinicians and patients should observe several safety considerations to minimize risks and ensure appropriate therapy.

• Verify blood glucose levels before each dose to avoid hypoglycemia.
• Adjust dose in patients with renal or hepatic impairment due to altered insulin clearance.
• Use caution in the elderly, as they may have reduced counter‑regulatory responses.
• Monitor for signs of allergic reactions, especially after the first injection.
• Educate patients on proper injection technique to prevent lipodystrophy.
• Consider reduced dosing during periods of decreased caloric intake or increased physical activity.
• Review concomitant medications that may potentiate insulin effects.

Humuline Regular Patroon may interact with other agents that influence glucose metabolism or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• Beta‑blockers that mask hypoglycemia symptoms.

Use with caution

• Oral hypoglycemic agents (e.g., sulfonylureas, meglitinides) that increase risk of low blood sugar.
• Thiazide diuretics that may raise blood glucose levels.
• Corticosteroids that can cause hyperglycemia, requiring dose changes.
• ACE inhibitors or ARBs that may potentiate insulin’s glucose‑lowering effect.
• Alcohol consumption, which can cause unpredictable glucose fluctuations.